Differentially expressed genes (adjusted P <0.01 ) in STAG2/LMO2 subtype compared to other T-ALL cases.

Differentially expressed genes (adjusted P <0.05) in three TLX3 subtypes (TLX3 γδ, TLX3 immature, TLX3 DP-like) compared to other T-ALL cases.

The gene expression profiles of γδ T-ALL.

Compounds used in single-dose (10uM) drug screening.

Differential peaks of H3K27ac and differentially expressed genes in gene-edited PF382 model.

The list of drugs for the patient-derived xenografts (PDX) cell screening.

Comparison of clinical characteristics and outcomes between gamma delta T-ALL and non-gamma delta T-ALL.

Lists of T-ALL related genes for filtering tumor-only and RNAseq samples.

Patient characteristics of 24 cases of STAG2/LMO2 subtype T-ALL that were performed genomic analysis.

The clinical features of γδ T-ALL.

Patient characteristics of 76 γδ T-ALL cases performed genomic analysis.

Up-regulated pathways in STAG2/LMO2 subtype compared to other T-ALL cases for mouse leukemia initiating cells (LIC) signatures analyzed by gene-set enrichment analysis (GSEA).

The genomic features of LMO2::STAG2 translocations.

Models for examining the effects of STAG2 inactivation.

Differentially expressed genes (adjusted P <0.01 ) of LMO2 γδ-like subtype vs other T-ALL.

Exploration of targets in STAG2/LMO2 T-ALL.

CRISPR editing construct sequences.

Fusion calls detected by RNA sequencing.

ChIP-seq coverage at the CD34 locus showing the effects of STAG2 inactivation.

Cox proportional hazards regression analysis of EFS and OS.